Erste Group downgraded Vertex Pharmaceuticals (VRTX) to Hold from Buy. The company’s ratio of inventories to sales has reached its highest level in the last 10 years, which is currently having a negative impact, the analyst tells investors in a research note. The firm says Vertex’s ratio of receivables to sales is also at a very high level.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Launches $4 Billion Stock Buyback
- Vertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy Rating
- Vertex Pharmaceuticals Holds Annual Shareholder Meeting
- Vertex Pharmaceuticals: Strong Growth and Promising Pipeline Justify Buy Rating
- Skechers, Shopify, Diamondback, Vertex, Turtle Beach: Trending by Analysts